Study scans past data: is cancer drug safe for failing kidneys?
NCT ID NCT07117409
Summary
This study looked back at medical records to see if the cancer immunotherapy drug nivolumab caused different side effects in people with advanced kidney cancer, depending on how well their kidneys were working. It included 81 patients who had already received the drug as part of their regular cancer care between 2017 and 2018. The main goal was to compare safety and side effects across three groups: patients with normal, moderately reduced, or severely reduced kidney function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda USL IRCCS di Reggio Emilia
Reggio Emilia, Italy
Conditions
Explore the condition pages connected to this study.